
Keywords: هیپر فسفاتمی; Phosphate binder; calcium acetate; lanthanum carbonate; sevelamer carbonate; sevelamer hydrochloride; hyperphosphatemia; chronic kidney disease (CKD); end-stage renal disease (ESRD); dialysis; drug efficacy; drug cost-effectiveness; health care costs; Med